Recent clinical findings to aid individuals with eczema and enhance their emotional well-being

On World Atopic Eczema Day, Phlecs presents an innovative treatment approach aimed at addressing both the skin condition and the emotional well-being of patients. 

Eczema (also known as atopic dermatitis) is a prevalent, chronic skin disorder characterized by symptoms such as dry skin, localized red scaly patches, intense itching, and skin discomfort. Its prevalence is substantial, affecting approximately 20% of children and up to 10% of adults. As of 2022, about 223 million people worldwide live with atopic dermatitis, with approximately 43 million of them being between the ages of one and four. The relentless itch often leads to frequent scratching, exacerbating skin damage and perpetuating a distressing cycle known as the “itch-scratch-itch” cycle. This condition’s burden can significantly impact an individual’s physical health, mental well-being, and overall quality of life.

Numerous clinical studies have been conducted on UV-free blue light therapy, demonstrating its safety, effectiveness, and gentleness in treating inflammatory skin conditions and alleviating itch without the adverse effects associated with medication or the risks posed by ultraviolet (UV) exposure. The Medical University of Łódź in Poland has undertaken clinical research involving 20 eczema patients who underwent 30-minute sessions of blue light therapy using Phlecs’ Full Body Blue Light device. The results of this study were presented at the International Congress of Atopic Dermatitis in Gdansk (August 30 – September 1 2023) and indicated significant improvements in patients’ conditions after just 10 treatments (data on file). On average, eczema symptoms, itching, and overall quality of life improved by 40% to 50%, reinforcing previous research findings. What’s novel is that blood sample analysis revealed a remarkable 96% increase in serotonin levels, which could potentially contribute to improved mood and mental health among patients.

David Aubert, CEO, and Co-founder of Phlecs, commented on these promising results, stating, “These findings are highly encouraging, and we anticipate further studies will confirm the long-term effectiveness and safety of blue light therapy. This marks the first time we’ve demonstrated that blue light may enhance serotonin production, providing insight into why patients find this treatment highly favorable. One of the current limitations of (UV-)phototherapy is that patients must visit a clinic for treatment, which can be time-consuming. To address this challenge, Phlecs is actively developing a new range of UV-free blue light home devices that will be introduced within the next few years. We are presently raising funds to support and accelerate our expansion.”

About Phlecs

Phlecs is a Dutch startup founded by four former employees of PHILIPS, each with extensive experience in photo-dermatology. Over the past 15 years, comprehensive clinical research has been conducted on UV-free LED lighting for photo-dermatology treatments. At Phlecs, we firmly believe that blue LED light represents an effective tool for physicians and patients to manage the symptoms of itching and inflammatory skin conditions in a safe, effective, and cost-effective manner. Our first full-body professional device is CE certified class IIa and is currently available in Poland, Germany, and Denmark. We anticipate expanding our sales to other EU countries soon.

For more information:

Phlecs receives a new grant from EIT Health to start sales in Germany

Twenty-nine scale-ups developing diverse healthcare technologies have been selected to participate in the Bridgehead programme. Among them is Phlecs, the Dutch start-up that addresses unmet needs in dermatology with UV-free phototherapy solutions.

More information through this link

Dutch MedTech start-up Phlecs receives the innovation award at the International Ageing Fit Conference in Lille (France)

Out of 25 European competing projects, Phlecs has received the innovation award at the Ageing Fit Conference on the 2nd of March 2022 for its Full Body Blue Light device ( ).”

More information through this link

PHLECS receives a 50,000€ grant from Metropoolregio Eindhoven

Phlecs initiates the development project of a new generation of phototherapy blue light – UV free medical device: the Full Body Home Connected.

After the launch of a research device in 2020, Phlecs has recently made significant progress in the clinical validation of the blue light therapy to treat senile pruritus (elderly itching) and atopic dermatitis (eczema). Thanks to the grant from Metropool regio Eindhoven, Phlecs can start the development of a connected home device that can capture patient  biomedical data for personalized treatment and will enable future artificial intelligence-based services.

More information through this link

Blue Light Therapy clinical investigations in Poland

Interview of Professor Lesiak at the Polish national television – May 2021
English subtitles available

The power of Blue Light – phototherapy for recovering from COVID-19


Blue light, emitted by LED lamps, is one of the phototherapy methods that has been recently enjoying great popularity, mainly in dermatology, but not only. Prof. Joanna Narbutt, Prof. Aleksandra Lesiak and Dr. n. med. Michał Chudzik undertook research on the application of blue light therapy in people who had been infected with COVID-19 but who were not hospitalized for this reason and hence did not regain full strength after the disease. Interview with Prof. Aleksandra Lesiak.

Professor, please tell me what is blue light that you use to treat patients?

Blue light, which we are talking about and which is also used in photodermatology, has a wavelength of 453 nanometers, which belongs to the visible light spectrum. Phototherapy has been used in dermatology for a long time, however we are looking for safer solutions. Currently, narrow band UVB at 311 nm and PUVA therapy is considered as the gold standard in phototherapy. It is effective and has been underpinned by a large body of scientific literature on this subject. However, ultraviolet light can cause damage on the DNA of the cell nucleus and bares a risk of inducing skin cancer. The mutagenic effect of blue light is very low. Therefore, it seems to be a safer form of phototherapy compared to UV irradiation.
Blue light therapy has anti-inflammatory and antipruritic (anti itch) properties. What is more is that it can also improve the mood by increasing the production of β-endorphins.
Interestingly, it is known that skin diseases worsen under stress. On the other hand, skin diseases themselves are the source of stress. People with visible manifestations of skin diseases are often stigmatized. Due to the chronic nature of some of them, patients often need the support of a psychologist or psychiatrist. That is why a holistic approach is so important. Blue light is part of this approach due to its biological ability to inhibit inflammation, as well as its relaxing and anti-stress effect. This is our hope for a breakthrough in the treatment of many skin diseases. The patients we treat at our center are patients with atopic dermatitis, psoriasis, eczema and chronic pruritus. In mid-February 2021, research using the device called PHLECS Full Body Blue has started. The group of study participants is getting bigger and the first data we are getting in are very promising.

Next to treatment of dermatological diseases, you have initiated research about the influence of blue light on complications after infection with the SARS-CoV-2 coronavirus. How does blue-light work in this case?

In consultation with cardiologists, we applied blue light therapy on patients treated in a post-covid clinic who developed complications. COVID-19, a disease caused by the SARS-CoV-2 coronavirus infection, is characterized by a wide spectrum of symptoms, and its course and late complications are not fully understood. There are reports that patients who have had COVID-19 and have not been hospitalized for this reason may develop persistent symptoms in the form of chronic fatigue, dyspnea, psychological stress, decreased quality of life, and psychiatric disorders (anxiety, depression), sleep, concentration and memory disorders).
Based on studies on the influence of the blue light therapy on the increase of β-endorphin levels, reduction of systolic blood pressure, improvement of endothelial function and arterial stiffness, together with representatives of PHLECS, the manufacturer of the Full Body Blue Light device, we hypothesized that blue light therapy could be beneficial for a range of these persistent symptoms.

Is the whole body irradiated during the session?

Patients receive half-hour illumination sessions 2-3 times a week. It is a very pleasant light with a soothing feeling of warmth. A substitute for staying on the beach on a sunny day, i.e. half an hour of such relaxation in a lying position. Patients are really satisfied. It is a kind of holistic pharmacology with a relaxing effect. I am going to undergo such exposure myself, because everything that is happening now has taken its toll on me. The COVID-19 situation is stressful for us all. I think that in the future, blue light can also be used to treat seasonal mood swings. In fact, light therapy is already used in psychiatry, but when delivered intraocular (i.e. via the eyes).

Where can people who want to take part in the survey apply?

We started the survey in February 2021. You can still apply at www.stop- However, it is important to remember about the inclusion criteria for the study, which only includes people who suffered from COVID-19, but were not hospitalized for this reason, and still experience symptoms 4 weeks after the end of the disease including fatigue (which is at least 50% higher compared to the what it was before the onset of COVID-19).

Adapted after using Google Translate, original article in Polish:

NEW STUDY ON BLUE LIGHT: The impact of non-toxic blue light (453 nm) on cellular antioxidative capacity, TGF-β1 signaling, and myofibrogenesis of human skin fibroblasts

Blue light even at longer wavelengths shows antifibrotic activity and may represent a suitable and safe approach in the treatment of fibrotic skin diseases including hypertrophic scarring and scleroderma.

Link to abstract

PHLECS winner of the EIT Health’s Bridgehead Global program 2020

Dutch MedTech start-up PHLECS has just been selected by EIT Health to participate in its Bridgehead Global program. After receiving the CE marking for its Full Body Blue Light device last March, PHLECS is now moving forward to its next business milestone: the introduction of this innovative therapy in the US next year.

Press release

PHLECS, a Dutch start-up that launches a new drug-free therapy for psoriasis

The Dutch MedTech start-up has just obtained the medical CE marking for the Full Body Blue Light Device and will start its commercialization in Europe from April 2020 onwards.

Press release

Phlecs, the first start-up to address patient unmet needs with UV free phototherapy treatments

Phlecs was founded last April 2019 in Eindhoven, the Netherlands and has completed last May the first financing round with private investors. We are now focusing on the ISO13485 certification of our Quality Management System and the CE marking of the full body device so we can expect to install early 2020 the first Phlecs Full Body Blue Light devices in dermatology clinics. For more information contact us directly